NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM
Updated: Sep 22, 2022
NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
A Phase I Study of BFCR4350A in People with Previously Treated Multiple Myeloma
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Sponsor
Multiple locations
International study
ClinicalTrials.gov Identifier: NCT03275103
Official Title: An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : September 7, 2017
Click here for details on ClinicalTrials.gov
Drug: Cevostamab
anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A
BFCR4350A
Drug: Tocilizumab
COMY 22 - Session 15: Abstract communications
AN ONGOING PHASE I STUDY SHOWS CLINICALLY MEANINGFUL ACTIVITY AND MANAGEABLE SAFETY OF CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE]
157 Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid
Hematology Disease Topics & Pathways:
Biological, Bispecific Antibody Therapy, Diseases, Therapies, Lymphoid Malignancies
Saturday, December 11, 2021: 12:00 PM
- Alabama: University of Alabama at Birmingham
- Arizona: Mayo Clinic Arizona
- California: University of California San Francisco
- California: City of Hope Duarte
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Tennessee: Sarah Cannon Research Institute Nashville
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: Memorial Sloan-Kettering Cancer Center New York
- Pennsylvania: University of Pennsylvania Philadelphia
Locations
United States, Alabama
United States, Arizona
United States, California
United States, Colorado
United States, Massachusetts
United States, New York
United States, Pennsylvania
United States, Tennessee
United States, Texas
Canada, Alberta
Canada, Ontario
Canada, Quebec
Europe
Spain
Australia, Victoria